As of Wednesday close, Arcutis Biotherapeutics Inc.’s (NASDAQ:ARQT) stock was down -$0.26, moving down -3.07 percent to $8.21. The average number of shares traded per day over the past five days has been 926,140 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.18 fall in that time frame. In the last twenty days, the average volume was 785,865, while in the previous 50 days, it was 1,074,062.
Since last month, ARQT stock retreated -22.47%. Shares of the company fell to $8.09 on 08/16/23, the lowest level in the past month. A 52-week high of $27.40 was reached on 03/01/23 after having rallying from a 52-week low of $7.25. Since the beginning of this year, ARQT’s stock price has dropped by -44.53% or -$6.59, and marked a new high 10 times. However, the stock has declined by -70.04% since its 52-week high.
ARQT stock investors should be aware that Arcutis Biotherapeutics Inc. (ARQT) stock had its last reported insider trading activity 78 days ago on May 31. Matsuda Masaru, the See Remark of the company, disposed of 1,830 shares for $7.80 on May 31. It resulted in a $14,278 divestment by the insider. Welgus Howard G. sold 8,500 shares at an average price of $13.97 on Apr 17. The insider now owns 165,825 shares following the transaction. On Apr 06, Director Welgus Howard G. sold 8,500 shares at $12.01 apiece. The transaction was valued at $102,085.
Valuation Metrics
The stock’s beta is 0.66. Besides these, the trailing price-to-sales (P/S) ratio of 80.36, the price-to-book (PB) ratio of 6.27.
Financial Health
In the three months ended June 29, Arcutis Biotherapeutics Inc.’s quick ratio stood at 8.10, while its current ratio was 8.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 2.48, and the total debt-to-equity ratio was 2.48. On the profitability front, the trailing twelve-month gross margin is 76.20% percent. Based on annual data, ARQT earned $2.93 million in gross profit and brought in $3.69 million in revenue.
In Arcutis Biotherapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $199.77 million against cash and short-term investments of $163.56 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ARQT’s revenue rose 100.0% to $2.78 million during the quarter, while net income inched up to $5.19 million. While analysts expected Arcutis Biotherapeutics Inc. to report -$1.25 quarterly earnings, the actual figure was -$1.16 per share, beating the consensus estimate by 7.20%. During the quarter, the company generated -$68.2 million in EBITDA. The liabilities of Arcutis Biotherapeutics Inc. were 240.18 million at the end of its most recent quarter ended June 29, and its total debt was $204.22 million. The value of shareholders’ equity is $61.65 million.
Technical Picture
This quick technical analysis looks at Arcutis Biotherapeutics Inc.’s (ARQT) price momentum. With a historical volatility rate of 58.67%, the RSI 9-day stood at 23.18% on 16 August.
With respect to its five-day moving average, the current Arcutis Biotherapeutics Inc. price is down by -12.57% percent or -$1.18. At present, ARQT shares trade -21.06% below its 20-day simple moving average and -23.98% percent below its 100-day simple moving average. However, the stock is currently trading approximately -4.09% below its SMA50 and -50.63% below its SMA200.
Stochastic coefficient K was 9.66% and Stochastic coefficient D was 10.20%, while ATR was 0.66. Given the Stochastic reading of 4.15% for the 14-day period, the RSI (14) reading has been calculated as 32.32%. As of today, the MACD Oscillator reading stands at -0.68, while the 14-day reading stands at -1.18.
Analyst Ratings
Needham launched its rating on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to a Buy in a note to investors on September 07, 2022. Arcutis Biotherapeutics Inc. (ARQT) has been rated Buy by analysts. According to 0 brokerage firms, ARQT is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Arcutis Biotherapeutics Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $44.50, the current consensus forecast for the stock is $22.00 – $57.00. Based on these forecasts, analysts predict Arcutis Biotherapeutics Inc. (ARQT) will achieve an average price target of $41.88.
